Neuronostics develops software technologies that apply AI and mathematical modeling to electroencephalography (EEG) data to assess seizure risk and support epilepsy diagnosis. The company’s platform focuses on extracting clinically meaningful biomarkers from routine EEG recordings. Its approach emphasizes rapid analysis and objective interpretation to assist clinical decision-making. Neuronostics positions its technology within regulated clinical and diagnostic contexts.

The technology processes EEG signals using advanced computational models that characterize underlying neural dynamics rather than surface-level features alone. By applying mathematical analysis and machine learning, the system generates digital biomarkers associated with epileptic activity and seizure susceptibility. These biomarkers can be derived from relatively short EEG recordings, enabling faster assessment compared to prolonged monitoring. The platform emphasizes reproducibility and consistency across patients and recording conditions.

Neuronostics targets epilepsy diagnosis, risk stratification, and clinical evaluation where timely and accurate interpretation of EEG data is critical. The platform is intended to support clinicians by augmenting traditional EEG review rather than replacing expert judgment. Its focus reflects growing interest in computational biomarkers that translate complex neural data into actionable clinical insight.